H. Lee Moffitt Cancer Center & Research Institute

Oncology & Cancer

Researchers find dual inhibitor may be safer for CLL patients

Chronic lymphocytic leukemia (CLL) is the most common leukemia in adults. One in four new leukemia cases are CLL. Early-stage CLL patients often do not require therapy, but for those with aggressive disease or who have failed ...

Oncology & Cancer

Study suggests more could benefit from CAR T-cell therapy

Chimeric antigen receptor T-cell therapy, or CAR T, has become a game changer for lymphoma and leukemia patients who have relapsed or become resistant to previous treatments. The therapy uses a patient's own immune cells ...

page 3 from 22